Regenxbio (RGNX) Estimates Raised At Barclays Following Legal Expert Call

Barclays analyst, Gena Wang, reiterated her Overweight rating on shares of Regenxbio Inc. (NASDAQ: RGNX) and raised her price target to $88 from $83 to reflect additional ~5.5yr AVXS-101 royalty from the EU and a higher price after hosting a call with a Patent Expert.

The analyst based this change in 6 key assumptions:
1) an additional ~3yr AVXS-101 royalty in the US that was not in the model
2) higher net price for AVXS-101 vs. our assumption of $1.9m
3) likely quicker uptake than expected based on Spinraza initial launch in SMA
4) progress from numerous partner programs
5) potential royalty from rh74 in DMD which was not in the model
6) high probability of positive outcome from wetAMD cohort 4 data (likely in 2q19).

For an analyst ratings summary and ratings history on Regenxbio Inc. click here. For more ratings news on Regenxbio Inc. click here.

Shares of Regenxbio Inc. closed at $45.81 yesterday.

You May Also Be Interested In

• LuxUrban Hotels Inc. (LUXH) PT Lowered to $4 at Jones Trading
• Bank of New York Mellon (BK) PT Raised to $63 at CFRA
• Hexcel Corp. (HXL) PT Lowered to $86 at Stifel